Synonym
Lonazolac Calcium; Floxan; Irritren;
IUPAC/Chemical Name
calcium 2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)acetate
InChi Key
CAQGVXNKMLYRMF-UHFFFAOYSA-L
InChi Code
InChI=1S/2C17H13ClN2O2.Ca/c2*18-14-8-6-12(7-9-14)17-13(10-16(21)22)11-20(19-17)15-4-2-1-3-5-15;/h2*1-9,11H,10H2,(H,21,22);/q;;+2/p-2
SMILES Code
O=C([O-])CC1=CN(C2=CC=CC=C2)N=C1C3=CC=C(Cl)C=C3.O=C([O-])CC4=CN(C5=CC=CC=C5)N=C4C6=CC=C(Cl)C=C6.[Ca+2]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
75821-71-5 (Lonazolac Calcium)
53808-88-1 (Lonazolac)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
663.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rubio Lotvin B, Ruíz Moreno JA, González Ansorena R, Ibarrola E, Uranga G, Benítez E. [Calcium lonazolac and blood loss in users of intrauterine devices. Preliminary report]. Ginecol Obstet Mex. 1986 Aug;54:221-4. Spanish. PubMed PMID: 3781294.
2: Deneke J, Luckow V, Guserle R, Pässler HH. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients. Int J Clin Pharmacol Ther. 1998 Aug;36(8):418-24. PubMed PMID: 9726694.
3: Raulf M, König W. Effects of the nonsteroidal anti-inflammatory compounds Lonazolac Ca, indomethacin and NDGA on inflammatory mediator generation and release from various cells. Immunopharmacology. 1990 Mar-Apr;19(2):103-11. PubMed PMID: 1693604.
4: Kullich W, Fromme K, Klein G. [Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases]. Wien Med Wochenschr. 1996;146(17):459-64. German. PubMed PMID: 9045528.
5: Pavelka K. [Lonazolac-Calcium. A new non-steroidal antirheumatic agent for the treatment of progressive polyarthritis. A long-term open controlled trial]. Fysiatr Revmatol Vestn. 1984 Apr;62(2):80-7. Czech. PubMed PMID: 6378745.
6: Riedel R. [Lonazolac-Ca = Calcium [3-(p-chlorophenyl)-1-phenylpyrazole-4[ -acetate 1 Pharmacological properties of a new antiinflammatory/antirheumatic drug (author's transl)]. Arzneimittelforschung. 1981;31(4):655-65. German. PubMed PMID: 6972772.
7: Dijs H, Verheyen G, Guastavino V, De Vroey T, Deckers K, Driessens M. Clinical experience with lonazolac-calcium in the treatment of osteo-arthritis. Acta Belg Med Phys. 1990 Oct-Dec;13(4):213-5. PubMed PMID: 2097865.
8: Janssen M, Van Leeuwen MH, Albrecht H, Dijkmans BA. A double-blind parallel group comparative study of lonazolac-calcium and diclofenac in patients with rheumatoid arthritis. Clin Rheumatol. 1988 Dec;7(4):545-7. PubMed PMID: 3246140.
9: Rainer G, Krüger U, Klemm K. [Synthesis and physico-chemical properties of lonazolac-Ca, a new antiphlogistic/antirheumatic agent]. Arzneimittelforschung. 1981;31(4):649-55. German. PubMed PMID: 6972771.
10: Georgescu C, Dumitrescu C, Dănău M, Spandonidis S, Costache G. Therapy with irritren in rheumatic degenerative diseases. Med Interne. 1986 Apr-Jun;24(2):147-51. PubMed PMID: 3487823.
